A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer

NCT07150767 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped The applicant voluntarily withdrew the case

Conditions

Locally Advanced Breast Cancer (LABC)

Interventions

BIOLOGICAL: BioTTT001 injection

Sponsor

Beijing Bio-Targeting Therapeutics Technology Co., Ltd